The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada
- 20 July 2007
- journal article
- Published by Elsevier BV in Vaccine
- Vol. 25 (29), 5399-5408
- https://doi.org/10.1016/j.vaccine.2007.04.086
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Model for Assessing Human Papillomavirus Vaccination StrategiesEmerging Infectious Diseases, 2007
- Estimating the long-term impact of a prophylactic human papillomavirus 16/18 vaccine on the burden of cervical cancer in the UKBritish Journal of Cancer, 2006
- Impact of Model, Methodological, and Parameter Uncertainty in the Economic Analysis of Vaccination ProgramsMedical Decision Making, 2006
- Chapter 13: Current findings from prophylactic HPV vaccine trialsVaccine, 2006
- Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UKCurrent Medical Research and Opinion, 2006
- Cost-effectiveness of Extending Cervical Cancer Screening Intervals Among Women With Prior Normal Pap TestsObstetrics & Gynecology, 2006
- Cost-effectiveness of Human Papillomavirus DNA Testing in the United Kingdom, The Netherlands, France, and ItalyJNCI Journal of the National Cancer Institute, 2005
- Interprovincial Differences in GDP Per Capita, Labour Productivity and Work Intensity: 1990-2003SSRN Electronic Journal, 2005
- Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysisBritish Journal of Cancer, 2003
- Epidemiologic Classification of Human Papillomavirus Types Associated with Cervical CancerThe New England Journal of Medicine, 2003